Dennis Ding
Stock Analyst at Jefferies
(1.78)
# 3,247
Out of 5,072 analysts
15
Total ratings
40%
Success rate
3.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $20.87 | -4.17% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $43.36 | -40.04% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $33.48 | -40.26% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $46.03 | +19.49% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.54 | +419.48% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $37.03 | -5.48% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $10.02 | +79.64% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.41 | +58.73% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.41 | +36.05% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $3.50 | +614.29% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $79.80 | -72.43% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $41.45 | -42.10% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $20.87
Upside: -4.17%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $43.36
Upside: -40.04%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $33.48
Upside: -40.26%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $46.03
Upside: +19.49%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.54
Upside: +419.48%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $37.03
Upside: -5.48%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $10.02
Upside: +79.64%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.41
Upside: +58.73%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.41
Upside: +36.05%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $3.50
Upside: +614.29%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $79.80
Upside: -72.43%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $41.45
Upside: -42.10%